Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SB 9200 in Treatment Naive HCV Infected Adults

Next Previous
X
Search
Trial Profile

A Phase 1a/1b Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SB 9200 in Treatment Naive HCV Infected Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inarigivir soproxil (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 31 Mar 2016 According to a Spring Bank Pharmaceuticals media release, data from this trial will be presented at the International Liver Congress 2015, 51st annual meeting of the European Association for the Study of the Liver (EASL).
    • 16 Nov 2015 Results published in the Media Release
    • 16 Nov 2015 According to a Spring Bank Pharmaceuticals media release, data from this trial has been presented at the 2015 American Association for the Study of Liver Diseases (AASLD) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top